Intratect

Human Normal Immunoglobulin, the active ingredient in Intratect, is an immunoglobulin presented as a solution for injection for intravenous use. It is used to replace deficient antibodies in patients with primary or secondary immunodeficiency and to modulate immune responses in conditions such as immune thrombocytopenic purpura and Kawasaki disease.

GNH USA supplies Intratect as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Intratect, a human normal immunoglobulin, is employed in disorders where antibody deficiency or immune dysregulation is present. - Primary immunodeficiency diseases: restores IgG levels and reduces the frequency of serious infections. - Secondary immunodeficiency: provides passive immunity to patients with acquired loss of antibodies. - Immune thrombocytopenic purpura (ITP): modulates the immune system to increase platelet counts. - Kawasaki disease: reduces systemic inflammation and helps prevent coronary artery complications.

Intratect may cause a range of infusion‑related and systemic reactions.

Common Side Effects: - Headache: mild to moderate, often occurring during or shortly after infusion. - Fever and chills: transient rise in body temperature. - Nausea or vomiting: gastrointestinal discomfort during infusion. - Fatigue or malaise: general feeling of tiredness. - Back or muscle pain: discomfort at the infusion site or surrounding muscles. - Hypertension: temporary increase in blood pressure.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Thromboembolic events: clot formation that can affect veins or arteries. - Acute renal failure: sudden loss of kidney function, especially with high‑dose regimens. - Aseptic meningitis: inflammation of the meninges without infection. - Hemolysis: destruction of red blood cells leading to anemia. - Severe thrombocytopenia: marked drop in platelet count.

Before initiating Intratect therapy, clinicians should assess patient-specific risk factors and monitor for adverse events. - Baseline IgG assessment: determine need for replacement therapy. - Infusion monitoring: observe for reactions during and after administration. - Renal function evaluation: check creatinine clearance, especially in high‑risk patients. - Thrombotic risk assessment: consider history of clotting disorders. - IgA deficiency screening: avoid in patients with anti‑IgA antibodies. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Intratect can interact with other agents that affect immune function or renal/hemodynamic status.

Major Interactions (Avoid): - Live vaccines: concurrent use may increase risk of infection. - Other immunoglobulin products: may cause antibody overload and increase adverse reactions.

Moderate Interactions (Monitor Closely): - High‑dose aspirin or NSAIDs: heightened risk of renal impairment. - Diuretics: may exacerbate fluid shifts during infusion. - Anticoagulants: monitor coagulation parameters as IVIG can affect platelet function.